Clinical trial
Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary…
NCT00016289 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00016289 |
|---|---|
| Title | Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| Official title | Phase II Study of Intraperitoneal Recombinant Human Interleukin-12 (rhIL-12) in Patients With Peritoneal Carcinomatosis (Residual Disease < 1cm) Associated With Ovarian Epithelial Cancer or Primary Peritoneal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer |
| Intervention type | Biological |
| Interventions | recombinant interleukin-12 |
| Enrollment | 30 |
| Start date | Jul 1, 2001 |
| Primary completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: